News
TEVA
14.11
-2.22%
-0.32
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
NASDAQ · 1d ago
Teva on track for seventh straight day of gains
Healthcare Teva on track for seventh straight day of gains. Stock is up 1.38% at $14.34. Teva stock has outperformed the broader S&P 500 market by rising 36.35% in the last 12 months. TEVA has risen 64.09% in last one month.
Seeking Alpha · 1d ago
HEFA, EFA, CHKP, TEVA: Large Inflows Detected at ETF
NASDAQ · 1d ago
'Supreme Court Unlikely To Limit Access To Abortion Pill' - Washington Post
The Supreme Court seemed unlikely to limit access to mifepristone, a key medication used in more than 60 percent of U.S. Abortions. A majority of justices expressed skepticism that the antiabortion doctors have standing to sue. The government and the drug company say the drug is overwhelmingly safe.
Benzinga · 2d ago
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has US$19.8b of debt on its balance sheet. Teva Pharmaceutical Industries grew its EBIT at 19% over the last year. The company has a debt to EBITDA ratio of 3.8, but its free cash flow is weaker than expected. The future profitability of the company will determine its ability to manage its debt.
Simply Wall St · 2d ago
Teva Pharmaceutical Industries: Potential Outweighs Concerns
Teva Pharmaceutical is deeply undervalued, trading at a 77% discount. Teva Pharmaceutical is an Israeli pharmaceutical company focused on affordable generic medicine. The company has a 50% gross margin and 20% operating margin. The new CEO's turnaround plan looks promising and I recommend a Buy on the company's shares.
Seeking Alpha · 3d ago
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
NASDAQ · 3d ago
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Jim Cramer says Raymond James Financial, Inc. Is now valued more highly than JPMorgan Chase & Co. The "Mad Money" host said he is very bullish on Uber Technologies. Cramer recommended buying Arm Holdings plc (NASDAQ:ARM) Cramer said he's not recommending to buy General Electric Company (NYSE:GE)
Benzinga · 3d ago
Weekly Report: what happened at TEVA last week (0318-0322)?
Weekly Report · 4d ago
FTC Files Amicus Brief in Asthma Inhaler Patent Dispute Involving Teva, Amneal; Commission Seeks to Address Teva's Patent Abuse to Promote Affordable Drugs, Generic Competition
Benzinga · 6d ago
*FTC Files Amicus Brief in Asthma Inhaler Patent Dispute Involving Teva, Amneal
Dow Jones · 6d ago
*FTC: Commission Seeks to Address Teva's Patent Abuse to Promote Affordable Drugs, Generic Competition
Dow Jones · 6d ago
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
NASDAQ · 03/21 16:29
Thursday's ETF with Unusual Volume: PPH
NASDAQ · 03/21 16:18
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
GSK Plc announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease medicines. The program will be implemented by January 1, 2025. In January, the HELP Committee criticized the four inhaler manufacturers over high prices.
Benzinga · 03/21 11:17
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
NASDAQ · 03/19 17:46
Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?
AstraZenecas move to cap at $35 the out-of-pocket costs that patients pay for the Symbicort inhaler. The British drugmakers shift follows a similar step last month by Boehringer Ingelheim. Sen. Bernie Sanders launched an investigation of inhaler prices in January.
The Wall Street Journal · 03/18 17:12
UPDATE 2-AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers
AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers at $35 per month in the U.S. High drug prices in the United States have been the subject of growing political scrutiny. UK-based AstraZeneca's cap will apply to its respiratory products portfolio.
Reuters · 03/18 11:38
Weekly Report: what happened at TEVA last week (0311-0315)?
Weekly Report · 03/18 09:18
Wednesday's ETF with Unusual Volume: EIS
NASDAQ · 03/13 19:51
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.